Du är här

2014-05-08

Actelion Pharmaceuticals Ltd: Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved

Actelion Pharmaceuticals Ltd / Actelion's Annual General Meeting of
Shareholders held in Basel, Switzerland -All Board proposals approved .
Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is
solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 08 May 2014 -
At today's Annual General Meeting (AGM) of Actelion Ltd (SIX: ATLN), held in
Basel, Switzerland, shareholders voted in favor of all proposals by the Board
of Directors with a significant majority.

The meeting was attended by 220 shareholders. A total of 62'836'116 shares or
52.25% of the total outstanding shares were represented.

Led by the Chairman of the Board, Jean-Pierre Garnier, the company presented a
review of the 2013 performance. Highlights included the strong financial
results, approval and subsequent successful launch of its new medicine
Opsumit®, continued demand for key products Tracleer®and Veletri®,
strengthening of its specialty franchise through the acquisition of US
company Ceptaris, and considerable progress in clinical development. The
chairman reminded the shareholders that Actelion once again created
substantial value in 2013, with a total shareholder return of 76%.

The shareholders approved the Business Report consisting of the Annual Report,
the Annual Statutory Accounts and the Consolidated Accounts for the year
2013.

A proposal by the Board to appropriate available earnings from capital
contribution and distribute as a dividend in the amount of CHF 1.20 per
registered share was passed by shareholders. The ex-dividend date will be 12
May 2014 and the payment will be made on 15 May 2014.

Shareholders endorsed the 2013 compensation report by way of consultative
vote.

The shareholders granted discharge to all members of the Board of Directors
and of the Senior Management.

A proposal by the Board to reduce share capital by cancellation of repurchased
shares was approved by the shareholders.

Actelion's shareholders re-elected all members of the Board which stood for
election for a term of office until the conclusion of the 2015 AGM. In
addition, the shareholders elected Mr. Jean-Pierre Garnier as Chairperson of
the Board and Werner Henrich, Jean-Pierre Garnier and John J. Greisch to the
Compensation Committee.

Mr. Armin Kessler did not stand for re-election at the 2014 AGM. Commenting on
his long service, Jean-Pierre Garnier, Chairman of the Board of Directors,
said: "Armin Kessler has served as an integral member of Actelion's Board of
Directors for 10 years. During this time his in-depth and vast knowledge of
the pharmaceutical industry as well as his mentoring skills have helped
Actelion to become the successful global player it is today. He has served
Actelion's shareholders well and we thank him for his dedicated service."

Following the AGM, the Board of Directors of Actelion comprises a total of 10
members: Jean-Pierre Garnier (Chairman), Juhani Anttila, Robert Bertolini,
Jean-Paul Clozel, Carl Feldbaum, John J. Greisch, Peter Gruss, Werner
Henrich, Michael Jacobi, and Jean Malo.

BDO AG, represented by Mr. Marc Schaffner, was elected as Independent Proxy
for a term of office until the conclusion of the 2015 AGM.

Ernst&Young was re-elected as the Company's statutory auditors for the
business year 2014.

Shareholders also approved the proposed revisions to the Articles of
Association, including the modifications which ensure compliance with the
Federal Council's Ordinance in relation to the "Minder initiative".

Specifically, shareholders agreed to the principles proposed by the Board with
regards to the remuneration of the members of the Board of Directors and the
Core Executive Committee. As a result, shareholders will be asked to vote on
a combination of binding and advisory votes at the 2015 AGM as follows:

* Binding approval of the maximum aggregate amount of the compensation for
the Board of Directors for the period until the 2016 AGM;
* Binding approval of the aggregate compensation amount for the Core
Executive Committee for 2016; and
* A non-binding consultative vote on the company's annual compensation report
2014, in which the amounts of the compensation received by the Board of
Directors and the Core Executive Committee, as well as further details
regarding the remuneration structure, will be disclosed.

###

NOTES TO THE EDITOR

ABOUT ACTELION LTD.

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery,
development and commercialization of innovative drugs for diseases with
significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH).
Our portfolio of PAH treatments covers the spectrum of disease, from WHO
Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous
medications. Although not available in all countries, Actelion has treatments
approved by health authorities for a number of specialist diseases including
Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in
patients suffering from systemic sclerosis, and mycosis fungoides in patients
with cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,400 dedicated professionals covering all
key markets around the world including the US, Japan, China, Russia and
Mexico, Actelion has its corporate headquarters in Allschwil / Basel,
Switzerland.

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as
part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All
trademarks are legally protected.

For further information please contact:

Andrew Jones
Director, Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
www.actelion.com

Press Release PDF
http://hugin.info/131801/R/1783819/611013.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Globenewswire

HUG#1783819

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.